ICU Medical (NASDAQ:ICUI) Price Target Raised to $209.00 at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price target upped by KeyCorp from $198.00 to $209.00 in a research report report published on Wednesday,Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock.

A number of other research analysts have also recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday. Jefferies Financial Group assumed coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 target price for the company. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday, November 12th. Finally, Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $173.00.

ICU Medical Trading Down 2.4 %

Shares of ICUI stock opened at $167.86 on Wednesday. The stock has a fifty day simple moving average of $176.43 and a two-hundred day simple moving average of $142.99. ICU Medical has a 52-week low of $82.82 and a 52-week high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.08 and a debt-to-equity ratio of 0.75.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This trade represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel Woolson sold 2,502 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,502 shares of company stock valued at $6,573,496. 6.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently added to or reduced their stakes in ICUI. Hexagon Capital Partners LLC boosted its holdings in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP lifted its position in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the last quarter. Innealta Capital LLC purchased a new position in ICU Medical during the second quarter worth $32,000. Motco purchased a new position in ICU Medical during the first quarter worth $29,000. Finally, Venturi Wealth Management LLC increased its position in ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 302 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.